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This case is of 54-year-old female with catatonic schizophrenia, characterized by treatment resistance to the
pharmacotherapy with olanzapine, risperidone, flunitrazepam, and ECT. Olanzapine and risperidone and
flunitrazepam did not improve her catatonic and psychotic symptoms, and induced the extrapyramidal symptoms.
The effects of ECT did not continue even for a month. However, the treatment with low-dose aripiprazole
dramatically improved the patient’s psychotic symptoms and extrapyramidal symptoms. The mechanisms
underlying the effects of low-dose aripiprazole in this case remain unclear, but unlike other antipsychotics,
aripiprazole is a dopamine D2 partial agonist. In this regard, our results suggest that aripiprazole has numerous
advantages, especially in cases of stuporous catatonia and a defective general status.Background
Catatonia, which is characterized by motoric immobility such
as catalepsy or stupor, mutism, negativism, is shown in about
10-15% of patients with schizophrenia [1]. Published works
to date demonstrate variable treatment with benzodiaze-
pines, electroconvulsive therapy (ECT), N-Methyl-D-Asparte
(NMDA) antagonists, and antipsychotics, even the atypical,
which remain discussed, because of worsening in symptom-
atology and increasing the risk of inducing neuroleptic malig-
nant symdrome [2-4]. Aripiprazole, a dopamine D2 receptor
partial agonist, is different from other atypical antipsychotics,
which are common profile of D2 receptor antagonist.
We present a patient of catatonic schizophrenia, which
was markedly improved on low-dose aripiprazole, after
failing to respond to olanzapine, risperidone, and ECT.Case presentation
A 54-year-old woman began to experience auditory halluci-
nations, including a voice admonishing her to deny herself,
and delusions of persecution and reference, and to with-
draw socially. She gradually entered a catatonic stupor with
insomnia and anorexia. Her mother took her to a mental
clinic, where she was diagnosed with catatonic-type* Correspondence: sasaki@faculty.chiba-u.jp
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reproduction in any medium, provided the orschizophrenia. She was prescribed risperidone 1 mg/day
and flunitrazepam 1 mg/day for approximately 4 months,
but her withdrawal and stupor state did not improve, and
she was referred to another hospital at 55 years of age. No
abnormalities were found in her general laboratory exami-
nations or brain CT. She reported having consistent patho-
logical experiences, such as hallucination and delusions,
and her diagnosis was confirmed as catatonic-type schizo-
phrenia according to the DSM-IVcriteria. We discontinued
her previous medications and prescribed olanzapine
20 mg/day and flunitrazepam 1 mg/day for approximately
2 weeks. However, her catatonic stupor with anorexia and
severe extrapyramidal symptoms was not improved. She
was referred to a general hospital, and began to receive
electroconvulsive therapy (ECT). The ECT treatment was
enforced twice for six weeks per week (total 12 times). The
treatment with ECT and risperidone 3 mg/day and flunitra-
zepam 2 mg/day almost completely eliminated her psych-
otic symptoms, and she was again able to take meals by
herself, but a high level of extrapyramidal symptoms
remained. She was transferred to our hospital. After an-
other month of ECT, however, she began to experience
auditory hallucinations, and delusions of persecution and
reference, along with stupor with insomnia and anorexia
again. We changed her drug regimen from risperidone and
flunitrazepam to only aripiprazole 3 mg/day. Two weeks
later, her catatonic stupor and psychotic symptoms were
dramatically improved without extrapyramidal symptoms.
She was again able to take meals alone and was able to gotd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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been treated with only 3 mg/day aripiprazole for 48 months.
She has no recrudescence of psychotic symptoms or extra-
pyramidal symptoms, and continues to help her mother
with the housework.
Discussion
This case is of 54-year-old female with catatonic schizo-
phrenia, characterized by treatment resistance to the
pharmacotherapy with olanzapine and risperidone and
flunitrazepam, and ECT. To our knowledge, this is the first
published report to show that the treatment-resistant
schizophrenic patient with the catatonic subtype was
improved, using ultra-low-dose aripiprazole. In this case,
olanzapine and risperidone and flunitrazepam did not
improve her catatonic and psychotic symptoms, and
induced the extrapyramidal symptoms. The effects of ECT
did not continue even for a month. However, the treatment
with low-dose aripiprazole dramatically improved the
patient’s psychotic symptoms and extrapyramidal symp-
toms. Although it has been reported that atypical antipsy-
chotics and benzodiazepines were effective for stuporous
catatonia [5], olanzapine and risperidone ,and flunitraze-
pam did not improve the psychotic symptoms of our
patient; moreover, they exacerbated her extrapyramidal
symptoms. Although benzodiazepines, such as lorazepam,
are the first choice for the catatonic features as well as
ECT [5], and their high-doses are frequently used, benzo-
diazepines might cause respiratory arrest. So we were not
able to used for it. The mechanisms underlying the effects
of low-dose aripiprazole in this case remain unclear.
Recently Vörös et al and Kirino reported that aripiprazole
is effective for catatonic stupor [6,7]. Also it has been
reported that ECT-aripiprazole combination therapy has
an excellent safety profile and therapeutic efficacy [8,9].
The present case responded to ECT but began to relapse
one month after the course of ECT. So without the effects
of ECT, it would be uncertain whether aripiprazole alone
could have resolved her long-term stupor state. In this
regard, our results suggest that aripiprazole might have
advantages, especially in cases of stuporous catatonia and a
defective general status like the present case.
Conclusion
We reported here a case of successful treatment using
low-dose aripiprazole monotherapy for a female patient
after the ECT in cases of stuporous catatonia and a
defective general status.
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